Clinical experience with the Lillehei-Kaster valve prosthesis.

Area of Science:

• Cardiovascular Surgery
• Biomaterials Science
• Clinical Outcomes Research

Background:

• The Lillehei-Kaster valve is a mechanical prosthetic heart valve.
• Evaluating long-term outcomes of prosthetic valves is crucial for patient management.

Purpose of the Study:

• To assess the clinical outcomes, including mortality and thromboembolism, of the Lillehei-Kaster valve in patients undergoing aortic and mitral valve replacement.

Main Methods:

• Retrospective analysis of 215 patients who received the Lillehei-Kaster valve over a 7-year period.
• Separate evaluation of outcomes for aortic valve replacement (81 patients) and mitral valve replacement (108 patients).
• Data collection included hospital mortality, long-term mortality, thromboembolic events, and actuarial survival.

Main Results:

• Aortic valve replacement: 21% hospital mortality, 5% long-term mortality, 2.6/100 patient-years thromboembolism, 96% 5-year survival.
• Mitral valve replacement: 20% hospital mortality, 13% long-term mortality, 5.0/100 patient-years thromboembolism, 81% 5-year survival.
• Majority of patients experienced clinical improvement; 15 had double-valve replacement, 11 had concurrent coronary revascularization.

Conclusions:

• The Lillehei-Kaster valve provided acceptable long-term survival and clinical benefit for both aortic and mitral valve replacement, despite significant early mortality.
• Thromboembolism rates were observed in both patient groups.
• Further research may focus on optimizing anticoagulation strategies to mitigate thromboembolic risks.